NHL accounts for approximately 8–10% of all paediatric malignancies and comprises a heterogeneous group of lymphoid neoplasms with diverse clinicopathological and biological profiles. Burkitt lymphoma constitutes around 40% of paediatric NHL cases in developed countries. Despite its aggressive behaviour and high-grade pathology, paediatric survival rates for BL have markedly improved due to significant advances in multi-agent chemotherapy regimens and enhanced supportive care protocols. In high-resource settings, the event-free survival (EFS) now ranges from 80-90%, depending on both the stage of the disease at diagnosis and the primary anatomical site of involvement. ⁽⁴⁾⁽⁵⁾